$AMRX News

Amneal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript

Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance

Amneal Pharmaceuticals Raises FY2026 Adj EPS Guidance from $0.95-$1.05 to $0.96-$1.06 vs $0.97 Est; Raises FY2026 Sales Guidance from $3.050B-$3.150B to $3.100B-$3.200B vs $3.103B Est

Amneal Pharmaceuticals Q2 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $796.197M Beat $768.206M Estimate

Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism

Amneal Pharma Secures FDA Approval For Additional Strengths And Vial Presentations Of Iohexol Injection; Co. Plans To Launch These Products In Q3 Of 2026

UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

Zambon And Amneal's Hopledo Receives Positive CHMP Opinion For Parkinson's Disease, European Launch Expected From October 2026

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amneal Pharmaceuticals Announces New Interim Results From Phase 4 Study Reinforcing Reported Benefits Of Parkinson's Treatment Crexont

Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)

Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?

2 Reasons AMRX is Risky and 1 Stock to Buy Instead

Amneal Pharmaceuticals' (NASDAQ:AMRX) Solid Earnings Are Supported By Other Strong Factors

Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Amneal Reports First Quarter 2026 Financial Results